Search - tctmd.com

Displaying 941 - 960 of 1588

Sort: Relevancy | Date

Presentation TCT 2017

Topic 4: At the Cusp of Diminishing Returns for CV Therapies - Personalized Approaches and New Frontiers

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Catheter-Based Ultrasound Renal Denervation: RADIANCE Trial Update

Presenter: Michael Böhm, Thomas F. Luscher, Laura Mauri

October 30, 2017

Presentation TCT 2017

Amulet: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy, Fabian Nietlispach

October 30, 2017

Presentation TCT 2017

Clinical Trials Using RAPID: Some POC Thoughts

Presenter: Schuyler Jones, Hiroyoshi Yokoi, Theodore Heise

October 30, 2017

Presentation TCT 2017

KONAs WAVE IV Randomized Trial: Principal Results and Lessons Learned

Presenter: Michael Böhm, Thomas F. Luscher, Melvin D. Lobo

October 30, 2017

Presentation TCT 2017

Topic 3: Chronic Total Occlusion PCI - What Level of Evidence Is Required for Widespread Acceptance: Hard Endpoints vs QOL Measures

Presenter: Robert A. Byrne, Gregg W. Stone, J. Aaron Grantham

October 30, 2017

Presentation TCT 2017

WATCHMAN: Data Synthesis and Ongoing Trials

Presenter: William A. Gray, Vivek Y. Reddy

October 30, 2017

Presentation TCT 2017

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, C. Michael Gibson

October 30, 2017

Presentation TCT 2017

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Presenter: Robert A. Byrne, Gregg W. Stone, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives

Presenter: Michael Böhm, Thomas F. Luscher, Felix Mahfoud

October 30, 2017

Presentation TCT 2017

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Presenter: William A. Gray, Vivek Y. Reddy, Kurt Huber

October 30, 2017

Presentation TCT 2017

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of Women

Presenter: Wayne B. Batchelor, George A. Mensah, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Presenter: Robert A. Byrne, Gregg W. Stone, Aaron V. Kaplan

October 30, 2017

Presentation TCT 2017

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of African American/Latina Populations

Presenter: Wayne B. Batchelor, George A. Mensah

October 30, 2017

Presentation TCT 2017

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: SCAI

Presenter: Wayne B. Batchelor, George A. Mensah, Cindy L. Grines

October 30, 2017

Presentation TCT 2017

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: STS/AATS

Presenter: Wayne B. Batchelor, George A. Mensah, Vinod H. Thourani

October 30, 2017

Presentation TCT 2017

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: AHA

Presenter: Wayne B. Batchelor, George A. Mensah, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Alternatives to Traditional P-value Testing: Bayesian Designs

Presenter: Eugene H. Blackstone, Stuart J. Pocock, Roseann M White

October 30, 2017

Presentation TCT 2017

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: ACC

Presenter: Wayne B. Batchelor, George A. Mensah, Pamela S. Douglas

October 30, 2017

Presentation TCT 2017

Beyond Time-to-First Event: Counting Multiple Events, Hierarchical Measures, and Weighted Composites

Presenter: Eugene H. Blackstone, Stuart J. Pocock, Jan G. P. Tijssen

October 30, 2017

Advertisement

Topic 4: At the Cusp of Diminishing Returns for CV Therapies - Personalized Approaches and New Frontiers

Catheter-Based Ultrasound Renal Denervation: RADIANCE Trial Update

Amulet: Data Synthesis and Ongoing Trials

Clinical Trials Using RAPID: Some POC Thoughts

KONAs WAVE IV Randomized Trial: Principal Results and Lessons Learned

Topic 3: Chronic Total Occlusion PCI - What Level of Evidence Is Required for Widespread Acceptance: Hard Endpoints vs QOL Measures

WATCHMAN: Data Synthesis and Ongoing Trials

Do the PIONEER and RE-DUAL Results Alter LAA Closure Decisions?

Topic 2: Outcomes Without a Clear Mechanism (Radial Mortality Benefit, Aspirin/Ticagrelor Interaction, and More)

Perspectives on Current Trials in Renal Denervation: Evolution of Design, Endpoints, and Objectives

Should the Improved Results With NOACs Compared to Warfarin Change LAA Closure Decisions?

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of Women

Topic 1: How Should We Evaluate Technologies in Their Infancy? TAVR, Renal Denervation, BVS, LAA Closure, Mechanical Circulatory Support, and More

Diversity in Clinical Trials (Lessons Learned, Future Directions): Inclusion of African American/Latina Populations

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: SCAI

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: STS/AATS

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: AHA

Alternatives to Traditional P-value Testing: Bayesian Designs

Professional Societys Mission to Enhance DIVERSITY in Clinical Trials, Education and the Workforce: ACC

Beyond Time-to-First Event: Counting Multiple Events, Hierarchical Measures, and Weighted Composites

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content